DaVita’s second quarter was met with a significant negative market reaction, as shares declined sharply despite management ...

DaVita has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Shares of DaVita Inc. DVA advanced 1.42% to $129.50 Friday, on what proved to be an all-around great trading session for the ...

US healthcare company DaVit has revealed it suffered a ransomware attack and a data breach earlier this year which saw ...

DaVita has notified over 1 million individuals that their personal and health information was stolen in a ransomware attack.

Q2 2025 Earnings Call Transcript August 5, 2025 DaVita Inc. beats earnings expectations. Reported EPS is $2.95, expectations ...

DaVita fell victim to a cyberattack back in March of this year during which time hackers gained unauthorized access to its ...

Learn more about whether Alignment Healthcare, Inc. or DaVita Inc. is a better investment based on AAII's A+ Investor grades, ...

Akebia Therapeutics reports strong Q2 2025 earnings, driven by Vafseo’s 55% sales growth. Explore plans for expanded patient access & trial updates.

Gain insights into DaVita Inc.'s Q2 2025 earnings call. Explore volume challenges, cost controls, cyber incident impact, and reaffirmed financial guidance.

DaVita beat Wall Street estimates for second-quarter profit on Tuesday, driven by demand for its kidney dialysis services.